PND39 COST-EFFECTIVENESS IN AMYOTROPHIC LATERAL SCLEROSIS REVISITED: THE CASE OF RILUZOLE

Reexamine cost-effectiveness of riluzole in the treatment of amyotrophic lateral sclerosis (ALS) in light of recent advances in disease staging and understanding of stage-specific drug effect. ALS was staged by the FT9 method. Stage-specific health utilities (EQ-5D, US valuation) were estimated from an institutional cohort, whereas costs and transition probabilities were informed by existing literature. Costs were disaggregated into recurring...